On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Tumor microenvironment
- Naïve T cells can infiltrate tumors (1)
- Naïve T cells can infiltrate tumors (2)
- Tertiary lymphoid structures in cancer
- Neoantigens from mutations
- Immunosuppressive features
- Cancer immunotherapy
- Interaction between cancer and immune system
- Tumor associated antigens
- Vaccines (1)
- Adoptive cell transfer (1)
- Adoptive cell transfer (2)
- Immune checkpoint blockers
- Vaccines (2)
- Immune aging
- Advanced age and malignant diseases
- T cell priming & immuno-surveillance of tumors
- Naïve T cell compartment in the elderly
- in vitro model of naïve CD8+ T cell priming
- in vitro model-experimental procedure
- in vitro model-advantages
- CD8+ T cell priming efficacy in the elderly
- Adjuvant and high quality CD8+ T cells
- Summary slide
Topics Covered
- T cell priming
- Modulation of T cell priming
- Tumor microenvironment
- Cancer immunotherapy
- Immune aging
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Appay, V. and Nicoli, F. (2017, November 30). Priming of T cell responses 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 17, 2025, from https://doi.org/10.69645/PHCJ9694.Export Citation (RIS)
Publication History
- Published on November 30, 2017
Financial Disclosures
- Prof. Victor Appay has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Francesco Nicoli has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Priming of T cell responses 2
Published on November 30, 2017
19 min
Other Talks in the Series: Immunotherapy of Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
Hi, this is Victor Appay speaking from
The National Institute of Health and Medical Research in France.
In the second part of my talk,
I will concentrate more on the relationship of
T cell priming in the context of tumour micro-environment,
and its application in the context of cancer immunotherapy and aging.
0:20
Now in this fourth part,
I will discuss about T cell priming in the context of the tumour micro-environment.
0:29
It has been shown that upon injection in mice,
naive cells can infiltrate directly tumours,
and this has been associated with an improved survival of the mice bearing the tumours.
0:45
Interestingly, increasing evidence support that tumours can support
the infiltration, activation, and effector differentiation of naive CD8 T cells.
Indeed, the adoptive transfer of naive tumour-specific CD8 T cells,
into tumour-bearing mice, has been associated with
the accumulation of activated CD8 T cells in the tumours,
the acquisition of effector function,
and the presentation of antigen to
these cells by cross-presenting antigen presenting cells.
Also, the recruitment of naive T cell within tumours has been shown to be
favoured by the presence of high endothelial venules or HEVs.
HEVs have been identified in a range of human tumours,
and usually their presence has been associated with
the observation of CD8 T effector cells, B cells,
Th1 cells within the tumours,
and organised into so-called tertiary lymphoid structures or TLS.